Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 7:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 2,071 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Memorial Sloan Kettering Cancer Center Clear all
Completed Not applicable Interventional Results available

Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis

NCT01383759
View directory record Official record
Conditions
Light Chain Deposition Disease (LCDD or MIDD), Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD), Monoclonal Immunoglobulin Deposition Disease (MIDD), Amyloidosis
Interventions
Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 13, 2026, 7:46 PM EDT
Completed Phase 2 Interventional Results available

Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma

NCT00712582
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Etoposide, carboplatin, ifosfamide, Rituximab, Ifosfamide, Etoposide, Carboplatin, Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 13, 2026, 7:46 PM EDT
Completed Not applicable Interventional

A Study of Stereotactic Body Radiotherapy (SBRT) and Surgical Stabilization for People With Cancer That Has Spread to the Bone

NCT05038124
View directory record Official record
Conditions
Metastatic Cancer
Interventions
Preoperative Stereotactic Body Radiotherapy (SBRT)
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 13, 2026, 7:46 PM EDT
Completed Phase 1 Interventional

Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

NCT00058435
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
abagovomab
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 13, 2026, 7:46 PM EDT
Recruiting No phase listed Observational

Impact of ICCAN on Cancer Treatment Completion and Quality of Life

NCT01742143
View directory record Official record
Conditions
Cancer Patients
Interventions
The Integrated Cancer Care Access Network (ICCAN), Usual and Customary Group (U&C)
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 80 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
11
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 13, 2026, 7:46 PM EDT
Completed Not applicable Interventional Results available

Internal Radiation Therapy in Treating Patients With Prostate Cancer

NCT00573833
View directory record Official record
Conditions
Prostate Cancer
Interventions
questionnaire administration, quality-of-life assessment, brachytherapy
Other · Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 13, 2026, 7:46 PM EDT
Completed No phase listed Observational

Physical Activity and Inactivity in Lung Cancer Survivors

NCT00582348
View directory record Official record
Conditions
Lung Cancer Survivors
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 13, 2026, 7:46 PM EDT
Active, not recruiting Phase 2 Interventional

Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors

NCT01873326
View directory record Official record
Conditions
Germ Cell Tumors
Interventions
Paclitaxel, Ifosfamide, Cisplatin, Mesna, Bleomycin, Etoposide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
13
States / cities
Los Angeles, California • Stanford, California • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 13, 2026, 7:46 PM EDT
Completed Early Phase 1 Interventional

Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study

NCT02145143
View directory record Official record
Conditions
Thyroid Carcinoma
Interventions
Vemurafenib, serial 124I PET/CT, thyrotropin alpha
Drug · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 13, 2026, 7:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

NCT02650648
View directory record Official record
Conditions
Neuroblastoma, High-Risk
Interventions
cyclophosphamide, NK cells, hu3F8, rIL-2
Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 13, 2026, 7:46 PM EDT
Active, not recruiting Phase 1 Interventional

Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

NCT04577326
View directory record Official record
Conditions
Malignant Pleural Mesothelioma (MPM)
Interventions
cyclophosphamide, CAR T cells
Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 13, 2026, 7:46 PM EDT
Active, not recruiting Phase 2 Interventional

Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis

NCT03315026
View directory record Official record
Conditions
Multiple Myeloma, AL Amyloidosis
Interventions
Siltuximab, The M.D. Anderson Symptom Inventory (MDASI)
Drug · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 13, 2026, 7:46 PM EDT
Completed Phase 2 Interventional Results available

Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer

NCT00459875
View directory record Official record
Conditions
Kidney Cancer
Interventions
sunitinib malate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced Oct 13, 2026, 7:46 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.

NCT02909036
View directory record Official record
Conditions
Multiple Myeloma, Amyloidosis
Interventions
Melphalan, Pegfilgrastim, Autologous Hematopoietic Progenitor Cell Transplant
Device · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 13, 2026, 7:46 PM EDT
Active, not recruiting Not applicable Interventional

COBRA: Cancer, Older Adults, Balance and Resistance Activities

NCT07011862
View directory record Official record
Conditions
Primary Cancer, Metastatic Cancer, Cancer
Interventions
Cancer, Older adults, Balance and Resistance Activities
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
65 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Middletown, New Jersey • Montvale, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 13, 2026, 7:46 PM EDT
Active, not recruiting Not applicable Interventional

A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer

NCT05053230
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Tumor, Thoracic Tumor, Thoracic Cancer, Gynecologic Cancer, Gynecologic Tumor, Melanoma, Ovarian Cancer
Interventions
IM@Home, Enhanced usual care
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 13, 2026, 7:46 PM EDT
Recruiting Phase 2 Interventional

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

NCT05534438
View directory record Official record
Conditions
Oligometastatic Breast Carcinoma, Breast Cancer, Metastatic Breast Cancer, Metastatic Breast Carcinoma, ER+ Breast Cancer, HER2+ Breast Cancer
Interventions
Stereotactic body radiotherapy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 13, 2026, 7:46 PM EDT
Completed Not applicable Interventional Results available

Safety of Stool Transplant for Patients With Difficult to Treat C. Difficile Infection

NCT02770326
View directory record Official record
Conditions
C. Difficile Infection, Cancer
Interventions
Fecal Microbiota Transplantation (FMT)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 13, 2026, 7:46 PM EDT
Completed Phase 2 Interventional Results available

Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma

NCT00737438
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 13, 2026, 7:46 PM EDT
Not listed Phase 2 Interventional

A Biobehavioral Intervention for Young Men With Testicular Cancer

NCT04150848
View directory record Official record
Conditions
Testis Cancer
Interventions
Goal-Focused Emotion Regulation Therapy (GET), Individual Supportive Psychotherapy (ISP)
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 39 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Irvine, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 13, 2026, 7:46 PM EDT
Completed Phase 1 Interventional

Ro 31-7453 in Treating Patients With Locally Advanced or Metastatic Solid Tumor

NCT00003755
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
MKC-1
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Oct 13, 2026, 7:46 PM EDT
Recruiting Phase 2 Interventional

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

NCT06057935
View directory record Official record
Conditions
Malignant Peritoneal Mesothelioma, Peritoneal Mesothelioma, Mesothelioma, Mesothelioma, Malignant, Malignant Mesothelioma
Interventions
Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
13
States / cities
Chicago, Illinois • Ann Arbor, Michigan • St Louis, Missouri + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 13, 2026, 7:46 PM EDT
Recruiting Phase 1 Interventional

A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)

NCT07698899
View directory record Official record
Conditions
Recurrent Medulloblastoma, Refractory Medulloblastoma, CNS Metastases, Central Nervous System Metastasis
Interventions
25 mCi 177Lu- DTPA-omburtamab
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years to 22 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 13, 2026, 7:46 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Older Breast Cancer Patients: Risk for Cognitive Decline

NCT03451383
View directory record Official record
Conditions
Cancer, Breast, Age-related Cognitive Decline, Cognitive Decline
Interventions
Not listed
Lead sponsor
Georgetown University
Other
Eligibility
60 Years to 105 Years · Female only
Enrollment
1,700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 13, 2026, 7:46 PM EDT